Concomitant radiation-doxorubicin administration in locally advanced and/or metastatic soft tissue sarcomas: preliminary results

Anticancer Res. 1991 Nov-Dec;11(6):2085-9.

Abstract

Doxorubicin was administered by continuous infusion at a dosage of 12 mg/sqm/day for 5 days concomitantly with radiation treatment (150 or 200 cGy/day for trunk or extremity lesions, respectively) for 5 days. The 5-day cycles were repeated every 3 weeks. Seventeen patients, 5 of whom were pretreated, entered the study; all were assessable for toxicity and 15 for response. The overall objective response rate was 46% (7/15): 1 complete and 6 partial responses. Response rate reached 54% in only non-pretreated patients (6/11) and 75% in patients with PS less than or = 2 (6/8). No disease progression was observed during treatment. The median duration of complete or partial responses was 28 weeks (range 5-86). Toxicity was low and treatment very well tolerated. In our preliminary analysis, the response rate obtained with this combined chemo-radiotherapic regimen was encouraging and the toxicity was acceptable.

MeSH terms

  • Adult
  • Aged
  • Combined Modality Therapy
  • Doxorubicin / therapeutic use*
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Radiotherapy / adverse effects
  • Radiotherapy Dosage
  • Sarcoma / drug therapy*
  • Sarcoma / pathology
  • Sarcoma / radiotherapy*
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / radiotherapy*

Substances

  • Doxorubicin